Download PDF

1. Company Snapshot

1.a. Company Description

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally.It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio.The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems.


Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion.The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery.It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology.


The company is headquartered in Schlieren, Switzerland.

Show Full description

1.b. Last Insights on KURN

Kuros Biosciences AG's recent performance has been driven by its strategic agreement with Medtronic Spinal Division, announcing an exclusive five-year sales agency agreement for MagnetOsTM in spine surgeries. This partnership is expected to expand Kuros' commercial reach and accelerate sales growth, leveraging Medtronic's established sales network. The agreement also includes collaborative marketing and support services, further enhancing Kuros' market presence. This significant development is likely to have a positive impact on Kuros' revenue and growth prospects.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Kuros Biosciences announces enrollment of first patient in ASTRA study – A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion

Dec -02

Source:

Card image cap

Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference

Nov -26

Source:

Card image cap

New Forecasts: Here's What Analysts Think The Future Holds For Kuros Biosciences AG (VTX:KURN)

Oct -17

Source:

Card image cap

Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025

Oct -16

Source:

Card image cap

European Market Insights Bénéteau And Two Other Stocks Possibly Priced Below Value Estimates

Oct -03

Source:

Card image cap

European Stocks Estimated Below Intrinsic Value

Oct -03

Source:

Card image cap

Kuros Biosciences debuts commercial launch of MagnetOs MIS Delivery System at SMISS 2025

Sep -30

Source:

Card image cap

Kuros statement on media inquiry concerning former Board member

Sep -18

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.50%)

6. Segments

Medical Devices

Expected Growth: 8.5%

Kuros Biosciences AG's 8.5% growth in Medical Devices is driven by increasing demand for orthobiologics and spinal fusion products, expansion into new markets, and strategic partnerships. Additionally, the company's focus on innovative products, such as its proprietary fibrin-PTH technology, and growing adoption of minimally invasive surgeries are contributing to its growth momentum.

7. Detailed Products

CHORDA

CHORDA is a novel, patented, dural sealant that helps to prevent cerebrospinal fluid (CSF) leaks following spinal surgery.

NEURODAC-1

NEURODAC-1 is a novel, patented, rhNGF-based therapy for the treatment of Alzheimer's disease.

KT1101

KT1101 is a novel, patented, neurotrophic factor-based therapy for the treatment of Parkinson's disease.

CHORDA-MITE

CHORDA-MITE is a novel, patented, dural sealant that helps to prevent cerebrospinal fluid (CSF) leaks following spinal surgery.

8. Kuros Biosciences AG's Porter Forces

Forces Ranking

Threat Of Substitutes

Kuros Biosciences AG operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.

Bargaining Power Of Customers

Kuros Biosciences AG's customers are primarily pharmaceutical and biotechnology companies, which have limited bargaining power due to the specialized nature of the company's products and services.

Bargaining Power Of Suppliers

Kuros Biosciences AG relies on a few key suppliers for raw materials and equipment, which gives them some bargaining power, but the company's specialized requirements limit the suppliers' negotiating power.

Threat Of New Entrants

The biotechnology industry has high barriers to entry, including significant capital requirements, specialized expertise, and regulatory hurdles, which limits the threat of new entrants.

Intensity Of Rivalry

The biotechnology industry is highly competitive, with many established players and new entrants vying for market share, which increases the intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 8.87%
Debt Cost 3.95%
Equity Weight 91.13%
Equity Cost 8.43%
WACC 8.04%
Leverage 9.73%

11. Quality Control: Kuros Biosciences AG passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Nanobiotix

A-Score: 5.3/10

Value: 10.0

Growth: 3.1

Quality: 8.8

Yield: 0.0

Momentum: 10.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Bavarian Nordic

A-Score: 5.1/10

Value: 6.4

Growth: 9.0

Quality: 7.4

Yield: 0.0

Momentum: 6.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
MedinCell

A-Score: 5.0/10

Value: 6.0

Growth: 7.0

Quality: 5.9

Yield: 0.0

Momentum: 9.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Galapagos

A-Score: 3.9/10

Value: 8.0

Growth: 2.9

Quality: 5.0

Yield: 0.0

Momentum: 3.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Kuros Biosciences

A-Score: 3.7/10

Value: 4.0

Growth: 6.9

Quality: 4.1

Yield: 0.0

Momentum: 7.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
MediWound

A-Score: 2.9/10

Value: 6.0

Growth: 3.3

Quality: 3.3

Yield: 0.0

Momentum: 3.5

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

30.64$

Current Price

30.64$

Potential

-0.00%

Expected Cash-Flows